Charles River Laboratories

Health Care Life Sciences Tools & Services Wilmington, Massachusetts Last filing Feb 18, 2026 · FY2025

                    Revenue
                    FY2025
                
$4.0B
                    3y CAGR +0.3%
                    
                    P15
                    
                    n/a
                    
                    Net income
                    FY2025
                
$-144.3M
                    Net margin -3.6%
                    
                    P8
                    
                    n/a
                    
                    Total assets
                    FY2025
                
$7.1B
                    ROA -2.0%
                    
                    P8
                    
                    n/a
                    
                    Operating cash flow
                    FY2025
                
$737.6M
                    
                    n/a

18 yrs · FY2008–FY2025 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s total assets.

Balance Sheet

Assets, liabilities, and equity

33 accounts · 1 year

Total assets $7.1B

Total liabilities $3.9B

Shareholders equity $3.2B

Account	2025	Trend
Assets
Cash and Cash Equivalents	3.0%
Accounts Receivable	9.9%
Inventory	4.2%
Prepaid Expenses	1.8%
Total Current Assets	20.3%
Property,Plant and Equipment	23.2%
Operating Lease Assets	5.1%
Goodwill	38.7%
Intangible Assets	4.8%
Long Term Investments	2.9%
Deferred Tax Assets	0.9%
Other Noncurrent Assets	4.1%
Total Assets	100.0%
Liabilities
Accounts Payable	2.1%
Accrued Liabilities	3.8%
Deferred Revenue	2.9%
Current Portion of Long Term Debt	0.0%
Operating Lease Liabilities	0.0%
Other Current Liabilities	3.1%
Total Current Liabilities	15.7%
Operating Lease Liabilities Noncurrent	6.1%
Deferred Tax Liabilities	1.3%
Other Noncurrent Liabilities	1.9%
Total Liabilities	55.0%
Equity
Preferred Stock	0.0%
Common Stock	0.0%
Additional Paid In Capital	27.3%
Retained Earnings	19.5%
Treasury Stock	0.0%
Accumulated Other Comprehensive Income	-2.4%
Noncontrolling Interest	0.1%
Total Stockholders Equity	44.4%
Total Liabilitiesand Equity	100.0%

Income Statement

Revenue, expense, and profitability

17 accounts · 1 year

Revenue $4.0B

Operating income $25.2M

Net income $-144.3M

Account	2025	Trend
IncomeStatement
Revenues Total Revenue	56.3%
Expenses Selling,General and Administrative	10.4%
Expenses Depreciation and Amortization	5.7%
Expenses Share Based Compensation	1.0%
Expenses Restructuring and Asset Impairment	1.4%
Other Income Expense Operating Income	0.4%
Other Income Expense Interest Income	0.1%
Other Income Expense Interest Expense	1.5%
Other Income Expense Other Income/expense	-0.3%
Other Income Expense Income Before Tax	-1.4%
Income Tax Income Tax Expense	0.6%
net Income net Income	-2.0%
net Income Comprehensive Income	0.0%
Earnings Per Share Basic Eps	-0.0%
Earnings Per Share Diluted Eps	-0.0%
Earnings Per Share Weighted Average Shares Basic	0.7%
Earnings Per Share Weighted Average Shares Diluted	0.7%

Cash Flow Statement

Operating, investing, and financing flows

21 accounts · 1 year

Operating cash flow $737.6M

Investing cash flow $-209.3M

Financing cash flow $-536.7M

Account	2025	Trend
CashFlow
Operating Activities net Income	-2.0%
Operating Activities Depreciation and Amortization	5.7%
Operating Activities Stock Based Compensation	1.0%
Operating Activities Deferred Income Taxes	-1.1%
Operating Activities Changes In Operating Assets and Liabilities	-0.3%
Operating Activities net Cash From Operating Activities	10.3%
Investing Activities Business Acquisitions	0.0%
Investing Activities Purchases of Investments	0.3%
Investing Activities Proceeds From Sale of Investments	0.1%
Investing Activities Other Investing Activities	-0.0%
Investing Activities net Cash From Investing Activities	-2.9%
Financing Activities Proceeds From Debt	17.2%
Financing Activities Repurchase of Common Stock	5.1%
Financing Activities Proceeds From Stock Issuance	0.0%
Financing Activities Tax Withholding On Stock Based Compensation	0.1%
Financing Activities Other Financing Activities	-0.2%
Financing Activities net Cash From Financing Activities	-7.5%
Cash Reconciliation Effect of Exchange Rate On Cash	0.3%
Cash Reconciliation net Change In Cash	0.1%
Cash Reconciliation Cash At Beginning of Period	3.0%
Cash Reconciliation Cash At End of Period	3.0%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 1 year

Ratio	2025
Profitability
Gross margin	—
Operating margin	+0.6%
Net margin	-3.6%
FCF margin	—
Growth
Revenue CAGR (3y)	+0.3%
Returns
ROE	-4.6%
ROA	-2.0%
ROIC	+0.9%
Liquidity
Current ratio	1.29x
Quick ratio	0.82x
Leverage
D/E	1.24x
Interest coverage	0.24x
Efficiency
Asset turnover	0.56x
Cash conversion cycle	—

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Charles River Laboratories

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history